Latest / Views and News with Clarence Ford / Insights from Rio's HIV conference & future of treatment in Africa
Transcript
- 0:00Speaker 1: In thirty eight, let's talk to our guest, Paul Miller
- 0:03Speaker 1: Sippler CEO. We're talking about the insights from the HIVY
- 0:07Speaker 1: conference in Brazil and the future treatment what it's going
- 0:09Speaker 1: to look like. Paul.
- 0:10Speaker 2: It's good to see you again, Terrence, thanks so much.
- 0:13Speaker 1: There's a couple of thoughts just in anticipationalist conversation. I
- 0:15Speaker 1: went through my brain. Nineteen ninety seven being in Melbourne,
- 0:18Speaker 1: Australia was at the time the third aid Impact Conference,
- 0:22Speaker 1: and I did a live broadcast from there, and I
- 0:26Speaker 1: think what they were spilling out for subside and Africa
- 0:29Speaker 1: specifically was doomed. It was really a crazy scenario that
- 0:35Speaker 1: I couldn't comprehend that HIV AIDS would come so close
- 0:39Speaker 1: to all of us, and it did. It did, and
- 0:42Speaker 1: I think the big talking point there was that anti
- 0:47Speaker 1: retrovirals would cast the patient's patient ten thousand Juish dollars
- 0:51Speaker 1: per year, which I think the implication that we all
- 0:55Speaker 1: had was that it was going to difficult for Africa
- 0:58Speaker 1: to access this this very important medication and how we
- 1:02Speaker 1: talked forty years later, but before we get there, then
- 1:06Speaker 1: I did a broadcast from your Danoon facility you just
- 1:10Speaker 1: after just after COVID, and I got to learn a
- 1:13Speaker 1: lot about what you do. And he says, it's about
- 1:16Speaker 1: the affordability of medication for Africans, is it it is?
- 1:19Speaker 2: At that time you're reflecting upon back in the nineties,
- 1:24Speaker 2: you rightly point out, you know, if you've got HIV
- 1:27Speaker 2: and AIDS in Africa, it was a death sentence. And
- 1:31Speaker 2: at the time we were seeing about eight thousand people
- 1:34Speaker 2: passing away on a daily basis, purely because access to
- 1:38Speaker 2: medicine just was not an option. It was unaffordable. And
- 1:42Speaker 2: I think what we've seen now is we've got more
- 1:45Speaker 2: than forteen million people globally living with HIV and AIDS.
- 1:50Speaker 1: That's the difference.
- 1:50Speaker 2: It's a big number. And in South Africa we've got
- 1:54Speaker 2: eight million people. And he has the good news. The
- 1:57Speaker 2: good news is of that eight million people, six million
- 2:01Speaker 2: on treatment. That means that every day they take one
- 2:05Speaker 2: pill each day, and that means that they will live
- 2:08Speaker 2: long and very prosperous lives. In fact, their life expectation
- 2:12Speaker 2: is equivalent to anybody else, barring other sickness.
- 2:16Speaker 1: It's not much that we can complement our government for,
- 2:19Speaker 1: but I think the role out eventually albeit sluggish initial
- 2:22Speaker 1: a sluggish response to the efficacy of anti retrovirals. It
- 2:27Speaker 1: could have been maybe implemented a lot earlier, but it
- 2:30Speaker 1: was the biggest such rollout in the world.
- 2:32Speaker 2: You know. I think we talk a lot about how
- 2:34Speaker 2: Africa and South Africa has to come up with innovation
- 2:38Speaker 2: because of the need, and I think we are. We've
- 2:42Speaker 2: proven ourselves in the fight against HIV, and I think
- 2:45Speaker 2: we've done incredibly well to think that we've got the
- 2:48Speaker 2: vast majority of people living with HIV on treatment. That
- 2:53Speaker 2: means that their viruses are so low inside their bodies
- 2:59Speaker 2: it's undetectable. If you put it in a microscope, a
- 3:02Speaker 2: modern one, you would not be able to really detect
- 3:05Speaker 2: that HIV virus in their body. The good news for
- 3:08Speaker 2: that means it's untransmittable. So they cannot transmit that virus
- 3:14Speaker 2: because it's undetectable. So the chances of them infecting somebody
- 3:18Speaker 2: else someone knew.
- 3:20Speaker 1: To stay eligible it's negligible, Okay, But I think the
- 3:23Speaker 1: important distinction is back in nineteen ninety seven people were
- 3:27Speaker 1: dying of it. They were and now we can unequivocally
- 3:30Speaker 1: say people are living with age to a normal ripe
- 3:33Speaker 1: old age. Okay. Also, you've brought the price of medication
- 3:38Speaker 1: down from ten thousand US dollars per year for a patient,
- 3:42Speaker 1: for a patient, for somebody living not a patient, let
- 3:44Speaker 1: me get this wording rate for a person living with
- 3:48Speaker 1: HIV AIDS. You brought that price downe quite considerably. What's
- 3:52Speaker 1: the price now since was it two thousand and one?
- 3:54Speaker 2: Yeah? Well, the price now, I mean I probably shouldn't
- 3:58Speaker 2: say it, but it's almost the price of a cup coffee.
- 4:01Speaker 1: I got it at three hundred and fifty dollars a year,
- 4:04Speaker 1: had one dollar a day.
- 4:05Speaker 2: Yeah, it's even less than that. It's gone down significantly
- 4:09Speaker 2: since those dollar a day, which was what happened in
- 4:12Speaker 2: two thousand at the time when medication was so limited
- 4:17Speaker 2: because of the price. Our chairman, doctor Hamid, at the
- 4:20Speaker 2: time made a commitment that he would make the drug
- 4:22Speaker 2: available at a dollar a day, which it was in
- 4:25Speaker 2: the early two thousands. Now, as we sit in twenty
- 4:28Speaker 2: twenty six, the price point is so low that it's
- 4:31Speaker 2: down to just over one hundred rand a month.
- 4:34Speaker 1: Wow.
- 4:34Speaker 2: So it's come down significantly and it continues to fall.
- 4:38Speaker 1: That is phenomenal. In nineteen ninety seven, Suppers breakthrough offer
- 4:42Speaker 1: that was two thousand and one at one dollar a day,
- 4:45Speaker 1: and again four years before that it was ten thousand
- 4:48Speaker 1: dollars per year one for treatment. And we're talking about
- 4:52Speaker 1: the we're talking about the triple therapy, right, so we
- 4:55Speaker 1: talked about the triple combination therapy.
- 4:57Speaker 2: Yeah, so it's called to offer limividing you take over.
- 5:00Speaker 2: It's so three active ingredients and it's it's one it's
- 5:06Speaker 2: one pill per day. That's at one pill per day
- 5:09Speaker 2: and and you your your life expecting to be extended.
- 5:13Speaker 2: What we are doing now is we're looking to say,
- 5:15Speaker 2: can we reduce the three active ingredients down to two,
- 5:19Speaker 2: making it even less expensive and more affordable, and on
- 5:24Speaker 2: top of that, reduced the side effect profile. And there's
- 5:27Speaker 2: even our talk of us bringing in what we call
- 5:29Speaker 2: a long acting injectable formulation where you would get an
- 5:33Speaker 2: injection once every two months, and this would cover your
- 5:36Speaker 2: treatment because the biggest challenge we face is adherence and
- 5:40Speaker 2: compliance and making sure that you take your tablet every day.
- 5:44Speaker 2: And if we can rather get a patient to move
- 5:47Speaker 2: towards one injection every two months, then the adherence and
- 5:51Speaker 2: compliances would be so much greater.
- 5:53Speaker 1: Okay, the other thing that you mentioned now you say
- 5:56Speaker 1: undetectable is ule. Is that a recent breakthrough in terms
- 6:02Speaker 1: of understanding it is?
- 6:04Speaker 2: And it's a It's a very important consideration because you
- 6:08Speaker 2: can bring HIV AIDS to an end if you get
- 6:12Speaker 2: the majority of people living with HIV and AIDS on treatment,
- 6:16Speaker 2: it means they will not be able to transmit the
- 6:18Speaker 2: disease to anybody else, and therefore HIV and AIDS can
- 6:21Speaker 2: come to an end. Now. Obviously the challenge we're facing
- 6:24Speaker 2: though is at the moment Clarence, we still got one
- 6:27Speaker 2: point five million people not on treatment.
- 6:31Speaker 1: Because they don't know, because it's not accessible because of
- 6:34Speaker 1: PAI far Why not?
- 6:35Speaker 2: It could be a multiple factors. Number one is ignorance.
- 6:38Speaker 2: You know, I'm just I'm not getting myself tested. It
- 6:41Speaker 2: could be I started my treatment and I find that
- 6:45Speaker 2: it was inconvenient and I actually don't feel sick, I
- 6:49Speaker 2: feel healthy. So it could be a multiple faceted reason.
- 6:54Speaker 2: Look for now, given what the government has done.
- 6:56Speaker 1: But Paper five is not part of that equation. No
- 6:59Speaker 1: American funding, not at all.
- 7:01Speaker 2: No, I don't believe. So. I think there's enough funding
- 7:05Speaker 2: for drug and there's enough funding for access and I
- 7:09Speaker 2: don't think that PEP files and actions are going to
- 7:13Speaker 2: have an impact on in terms of drug access. It
- 7:16Speaker 2: may impact other support services like awareness testing campaigns, bringing
- 7:24Speaker 2: people's attention to the disease, helping small groups like that
- 7:30Speaker 2: maybe are marginalized in society to help bring them in
- 7:34Speaker 2: and get treatment, but the overall access to drug I
- 7:37Speaker 2: don't think will be impacted by it.
- 7:40Speaker 1: So Simpler broke that patent CHOKEOL, they forced a total
- 7:44Speaker 1: paradigm shift and the affordability would then vest in what
- 7:50Speaker 1: used to be the response. But I see there's there's
- 7:52Speaker 1: there's new cutting edgsry responses, there's more injectibles, there's an
- 7:55Speaker 1: injection that you take twice a year, so it's not
- 7:57Speaker 1: the daily routine anymore. When do we get to the
- 8:00Speaker 1: cutting edge cut?
- 8:00Speaker 2: So that's now a whole new front of attacking HIV
- 8:05Speaker 2: because we realize every single day in South Africa there
- 8:09Speaker 2: are five hundred new patients acquiring HIV and AIDS five
- 8:16Speaker 2: hundred a day. So obviously the treatment and the untransmittable
- 8:23Speaker 2: aspects are being limited because not everyone's getting onto treatment.
- 8:27Speaker 2: So now we have to start thinking about how do
- 8:29Speaker 2: we prevent new infections? So The best way to do that,
- 8:34Speaker 2: if you can, is get someone to take a bit
- 8:38Speaker 2: of an active drug on a daily basis or once
- 8:43Speaker 2: every six months through an injection, and that would give
- 8:46Speaker 2: them complete coverage that they would not contract HIV and
- 8:50Speaker 2: AIDS from someone who's infected. Is that the oral prep
- 8:54Speaker 2: it is it's the oral prep and it's the injectable prep.
- 8:57Speaker 2: So this is prophylaxis. You take it on a monthly
- 9:01Speaker 2: basis or you take it on a twice a year,
- 9:04Speaker 2: So you would go in and get len a cap
- 9:07Speaker 2: of it, you would get an injection of it. It
- 9:09Speaker 2: would cover you for six months, and you would get
- 9:11Speaker 2: another injection cove you for another six months.
- 9:13Speaker 1: But we have other sdis the condom was useful in
- 9:16Speaker 1: the prevention of contracting those SDIS kind of a very
- 9:20Speaker 1: important part of the response.
- 9:22Speaker 2: Still true, and you know, Clarence, if you don't want
- 9:26Speaker 2: to be infected, use a condom, and you have to condomize.
- 9:30Speaker 2: There is no other way around it. And if you
- 9:32Speaker 2: want to prevent and stop yourself from contracting STDs like
- 9:38Speaker 2: Committea gonorrhea, the only way to prevent that is to
- 9:41Speaker 2: use a condom. There's nowhere around it. And Similarly with
- 9:44Speaker 2: HIV and AIDS, the best way to prevent contracting it
- 9:47Speaker 2: is using a condom. But if you don't and you
- 9:51Speaker 2: fail not to use it, then that's why preps available
- 9:54Speaker 2: that you are able to take a monthly or a
- 9:59Speaker 2: twice you injectable and completely prevent that infection happening.
- 10:04Speaker 1: I'm fascinated that the central takeaway from Age twenty twenty
- 10:10Speaker 1: six in Brazil was that developing game changing medicine is
- 10:15Speaker 1: only half of the battle, but ensuring sustainable voluntary licensing,
- 10:20Speaker 1: local manufacturing and equitable distribution to global health systems is
- 10:25Speaker 1: what actually saves millions of lives, and that positions you
- 10:28Speaker 1: absolutely suitably for a quicker response on patent medicines.
- 10:33Speaker 2: Yeah so we more recently, merk has just given access
- 10:39Speaker 2: to a very important drug called ali metrova, and Sippler
- 10:44Speaker 2: was fortunate to be chosen as one of those that
- 10:48Speaker 2: would manufacture it in South Africa and get access to
- 10:51Speaker 2: the innovation. And this is the drug we spoke about
- 10:54Speaker 2: where pretension, you could take it once a month and
- 10:57Speaker 2: prevent yourself from ever contract HIV and AIDS, and I
- 11:02Speaker 2: think this has to continue. The innovator companies have to
- 11:06Speaker 2: continue to build and to establish new treatment modalities for
- 11:11Speaker 2: HIV and AIDS, But most importantly, generic companies like Sippler
- 11:15Speaker 2: need access to those molecules to make them affordable.
- 11:19Speaker 1: So what we've seen, I just want to understand how
- 11:22Speaker 1: geopolitical shifts or maybe even international donor funding consolidation has
- 11:27Speaker 1: impacted our provision of healthcare and how you are positioning
- 11:30Speaker 1: as Siffler and response to that.
- 11:33Speaker 2: So the pressure on local government is getting larger and
- 11:37Speaker 2: larger to actually become more independent and self reliant. And
- 11:41Speaker 2: I think South Africa has done incredibly well at being
- 11:45Speaker 2: independent from international funding, and so you've see the South
- 11:48Speaker 2: African government response has been very very strong. We mentioned
- 11:52Speaker 2: about more than six million people on treatment and I
- 11:55Speaker 2: think that remains a very important prerogative that the government
- 11:59Speaker 2: remains committed to making sure that everyone who has been
- 12:03Speaker 2: tested and has been diagnosed with HIV and AIDS goes
- 12:06Speaker 2: on to treatment, and I think that continues. The challenge
- 12:10Speaker 2: we face now is how do we make sure across
- 12:12Speaker 2: the continent of Africa that every government prioritizes the treatment
- 12:17Speaker 2: of HIV and AIDS and realizes that they cannot no
- 12:20Speaker 2: longer be dependent upon organizations like PEP file.
- 12:24Speaker 1: And my guess is Paul Miller SI plus CEO, are
- 12:26Speaker 1: we talking well. He's bringing with him insights from Brazil,
- 12:31Speaker 1: insights from the HIV conference that happened there, and he's
- 12:34Speaker 1: giving us an insight into what the future of treatment
- 12:37Speaker 1: could look like across Africa. You should be in Durban,
- 12:41Speaker 1: there's a sad A conference. This is where the greatest
- 12:44Speaker 1: consernation of HIV positive people are. Are we as a
- 12:49Speaker 1: collective at least a SADEGG looking at a collective response?
- 12:53Speaker 2: So you are right, Southern Africa holds the greatest incidence
- 12:59Speaker 2: of HIV AIDS and I do think that we need
- 13:03Speaker 2: to continue to work as a collective in terms of
- 13:05Speaker 2: fighting it. And one of those actions we should be
- 13:08Speaker 2: taking is looking at prioritizing local manufacturing of HIV and
- 13:13Speaker 2: AIDS medication in Africa. It gives two things. One is
- 13:16Speaker 2: it gives complete independence in terms of being dependent upon
- 13:22Speaker 2: other manufacturers globally. And secondly, also it brings a viable
- 13:27Speaker 2: sustainable economy in terms of local manufacturing and the halo
- 13:31Speaker 2: effect that that brings in terms of obviously employment, skill sets,
- 13:36Speaker 2: technical capabilities is very important. We have our facility in Durban, ironically,
- 13:43Speaker 2: and we've been investing very heavily in there, trying to
- 13:46Speaker 2: grow and expand it to take advantage of this opportunity.
- 13:49Speaker 1: It is ten fifty one. Very special guest. Paul Moller
- 13:52Speaker 1: will be able to respond to your questions if you
- 13:54Speaker 1: have any you welcome via what's happened? Oh seven two
- 13:57Speaker 1: five six seven one five six seven you can call
- 14:00Speaker 1: to act directly with Paul two one four four six
- 14:02Speaker 1: five sixty seven Ernest, Right, Wow, that's amazing. Do you
- 14:06Speaker 1: then foresee a future where this drug can be used
- 14:09Speaker 1: as a vac from childbirth like they do with a
- 14:12Speaker 1: girl for cervical cancer?
- 14:14Speaker 2: Interesting? Yeah, you know, do you take.
- 14:18Speaker 1: It back to the womb? I'm worried about that.
- 14:20Speaker 2: Yeah. Look, I think the prevention aspects for young children.
- 14:24Speaker 2: You're right, particularly as a young child when it's in
- 14:28Speaker 2: the womb. The treatment of the mother remains paramount importance,
- 14:33Speaker 2: and we are seeing the government has done a big,
- 14:35Speaker 2: strong intervention at the very early during the gestation period
- 14:39Speaker 2: to cover the mother and make sure she doesn't transmit
- 14:41Speaker 2: the disease to her child.
- 14:42Speaker 1: We've been effective on that front. We have.
- 14:45Speaker 2: Very effective in terms of giving it very young. It's
- 14:50Speaker 2: an important conversation because we know the highest incidence of
- 14:53Speaker 2: new infections sits between the ages of fifteen and twenty five.
- 14:58Speaker 2: So definitely, as the child becomes sexually active, you've got
- 15:03Speaker 2: to start thinking about prevention and not treatment. Rather stop
- 15:08Speaker 2: the transmission to those young people and protect them. And
- 15:12Speaker 2: I think this oral medication and len a cap of
- 15:15Speaker 2: as an ejectable will definitely stem those cross infections.
- 15:20Speaker 1: Yes, Raswanso, can you see a future where HIV disappears
- 15:24Speaker 1: almost entirely?
- 15:26Speaker 2: So we set ourselves a vision right that in the
- 15:29Speaker 2: twenty thirties that we will see HIV come to an end.
- 15:32Speaker 2: I don't know if we can claim that it will
- 15:35Speaker 2: completely disappear, but it will move from being a pandemic
- 15:39Speaker 2: to be becoming a treatable disease, much like hypertension diabetes.
- 15:44Speaker 2: Is that we will be able to control it and
- 15:47Speaker 2: treat it. There is talk about a vaccine and the
- 15:51Speaker 2: hope that a vaccine will be developed. However, HIV is
- 15:55Speaker 2: a virus, is a very tricky virus To treat with
- 15:58Speaker 2: a vaccine effective that would be and bring about a
- 16:02Speaker 2: cure and an end. I'm not sure, but definitely. The
- 16:06Speaker 2: treatment is highly effective where vast majority of people on
- 16:11Speaker 2: treatment are controlled and suppressed with their virus, and we
- 16:15Speaker 2: know now no that we can stop transmission to healthy
- 16:18Speaker 2: people by taking protection through a medication or objectable.
- 16:24Speaker 1: So I think there's a lot of optimism that came
- 16:27Speaker 1: out of out of Brazil, and I think we are
- 16:32Speaker 1: also looking at a let's call it a holistic response,
- 16:36Speaker 1: maybe seeing SDI as part of the equation. There's vital
- 16:41Speaker 1: hepatitis and non communic communicable diseases. How simpler adapting adapting
- 16:46Speaker 1: its portfolio support integrated primary healthcare delivery.
- 16:51Speaker 2: So it goes hand in hand right. Sexually transmitted diseases
- 16:56Speaker 2: and HIV are a linked. Typically, if you have an STD,
- 17:00Speaker 2: you are more likely to contract HIV, and probably just
- 17:04Speaker 2: your behavior may put you at risk. What we are
- 17:09Speaker 2: seeing though, is the biggest challenge apart from STDs, is
- 17:13Speaker 2: that access to the medicine. And what we really spend
- 17:17Speaker 2: a lot of time focusing on clearnce is how do
- 17:19Speaker 2: we get the drug from the government to the patient.
- 17:23Speaker 2: For a patient to take a day off work to
- 17:26Speaker 2: go and get their medication once every two or three months,
- 17:30Speaker 2: it's just not functional and so What we have done
- 17:32Speaker 2: is we've established these pickup points, over fifty of them
- 17:35Speaker 2: around the country in taxi ranks, in places where people
- 17:40Speaker 2: congregate that you can go there and within ten minutes
- 17:44Speaker 2: you can collect to your medication. It's not labeled. It
- 17:48Speaker 2: comes in a white label, so.
- 17:50Speaker 1: Not a dispensary. You're not dealing with people.
- 17:52Speaker 2: You not have to cure at the hospital and spend
- 17:55Speaker 2: ages at a hospital waiting for medicines, and you know
- 17:57Speaker 2: when you go there every month, the medicine is there
- 18:00Speaker 2: and it's.
- 18:01Speaker 1: Available and uptake. Are people using the service increasing?
- 18:05Speaker 2: Absolutely, it's it's increasing. It's a it's a government initiative
- 18:09Speaker 2: which we've been partnering with them, and it is being
- 18:13Speaker 2: more and more widespread. We're also looking at other alternatives,
- 18:17Speaker 2: like where you put a code into a post box
- 18:20Speaker 2: and you open up the post box and your medications inside.
- 18:24Speaker 2: So we're looking at other innovations to make sure that
- 18:27Speaker 2: HIV medicines, along with other chronic therapies like diabetes and hypertension,
- 18:32Speaker 2: will be made available through these pickup points around the country.
- 18:36Speaker 1: Let's talk about the suppler again, just in terms of
- 18:38Speaker 1: again international donor funding is seeing unprecedented pressure. Let's just
- 18:44Speaker 1: call it that. Maybe you know what are those sustainable
- 18:49Speaker 1: market based even public private initiatives that can keep generic
- 18:54Speaker 1: R repricing I think first and foremostly low, but make
- 18:57Speaker 1: it viable for your shielders as well.
- 18:59Speaker 2: Yeah, so I think the big focus we have right
- 19:03Speaker 2: now is making sure that local manufacturing goes ahead because
- 19:08Speaker 2: we can get the product closer to the patient. It
- 19:12Speaker 2: also allows us to control the costs and to actually
- 19:15Speaker 2: set the manufacturing facilities up in a way that they
- 19:18Speaker 2: run efficiently and that they're fit for purpose for Africa,
- 19:22Speaker 2: and that's a big critical focus for us. We're also
- 19:26Speaker 2: looking at reducing the number of active drugs in treatment.
- 19:31Speaker 2: So you spoke about the triple combination TLD and we
- 19:36Speaker 2: try to reduce that now down to two instead of
- 19:39Speaker 2: three active ingredients. That will bring the price point down
- 19:43Speaker 2: even further and adherence will be improved. And then we
- 19:47Speaker 2: also mentioned about the injectable, the long acting injectible that
- 19:51Speaker 2: you can take once every two months for treatment. That
- 19:54Speaker 2: will improve adherence as well. So these are all the
- 19:57Speaker 2: initiatives to keep price points down, improve adherence and compliance
- 20:02Speaker 2: to treatment so that you keep your virus suppressed. And
- 20:06Speaker 2: on top of that look at more affordable ways in
- 20:08Speaker 2: which you can get access to your medication.
- 20:11Speaker 1: And your business model remains. We're not reinventing the wheel.
- 20:13Speaker 1: We are just getting going to get the wheel out cheaper. Yeah,
- 20:16Speaker 1: that's it, and I think that's the solution that Africa seeks,
- 20:19Speaker 1: together with its own ability to cultivate its own genetic
- 20:22Speaker 1: databases and find its own responses to the challenges that
- 20:26Speaker 1: are uniquely African.
- 20:27Speaker 2: I guess yeah. And we've seen that, right. We're seen
- 20:30Speaker 2: that the way in which doctors in the America healthcare
- 20:34Speaker 2: sector has responded to this pandemic and treated it. We've
- 20:38Speaker 2: seen the innovation in terms of apps. We've seen the
- 20:42Speaker 2: innovation in terms of how people get access to medication,
- 20:45Speaker 2: the price points. These are all home grown initiatives, born
- 20:51Speaker 2: out of a desperate need and the response within South
- 20:54Speaker 2: Africa has been absolutely phenomenal and it's made such an
- 20:57Speaker 2: impact in terms of those living with HIVN Paul.
- 21:00Speaker 1: It's been a fascinating conversation. We're gonna have to wrap
- 21:02Speaker 1: it up or Lee standing by with Eyewitness News at
- 21:06Speaker 1: eleven o'clock, can't believe it simpler. Coot giving us some
- 21:09Speaker 1: insights into Brazil twenty twenty six and all the things
- 21:14Speaker 1: that went down there. I think there's a sense of
- 21:16Speaker 1: optimism in twenty twenty six that we didn't see nineteen
- 21:19Speaker 1: ninety six.